Search Results - "Johnson, Keith M."

The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing by Jones, Clifford D., Andrews, David M., Barker, Andrew J., Blades, Kevin, Daunt, Paula, East, Simon, Geh, Catherine, Graham, Mark A., Johnson, Keith M., Loddick, Sarah A., McFarland, Heather M., McGregor, Alexandra, Moss, Louise, Rudge, David A., Simpson, Peter B., Swain, Michael L., Tam, Kin Y., Tucker, Julie A., Walker, Mike

“…Describes the optimisation of an imidazole amide series, leading to the identification of ( S)- 15b (AZD5597) as a candidate for further development. The…”
Get full text

Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life by Pike, Kurt G., Allen, Joanne V., Caulkett, Peter W.R., Clarke, David S., Donald, Craig S., Fenwick, Mark L., Johnson, Keith M., Johnstone, Craig, McKerrecher, Darren, Rayner, John W., Walker, Rolf P., Wilson, Ingrid

“…The continued discovery of a novel series of pyridine acid containing glucokinase activators is described. The composite parameter of unbound clearance was…”
Get full text

Design of a potent, soluble glucokinase activator with excellent in vivo efficacy by McKerrecher, Darren, Allen, Joanne V., Caulkett, Peter W.R., Donald, Craig S., Fenwick, Mark L., Grange, Emma, Johnson, Keith M., Johnstone, Craig, Jones, Clifford D., Pike, Kurt G., Rayner, John W., Walker, Rolf P.

“…The optimisation of a series of glucokinase activators is described, including attempts to uncouple the relationship between potency and plasma protein…”
Get full text

Discovery, synthesis and biological evaluation of novel glucokinase activators by McKerrecher, Darren, Allen, Joanne V., Bowker, Suzanne S., Boyd, Scott, Caulkett, Peter W.R., Currie, Gordon S., Davies, Christopher D., Fenwick, Mark L., Gaskin, Harold, Grange, Emma, Hargreaves, Rod B., Hayter, Barry R., James, Roger, Johnson, Keith M., Johnstone, Craig, Jones, Clifford D., Lackie, Sarah, Rayner, John W., Walker, Rolf P.

“…[Display omitted] The identification, synthesis and SAR of a novel series of glucokinase activators is described. The interplay between lipophilicity, potency…”
Get full text

Hippocampal Volume and Cardiovascular Risk Using the QRISK2 Prediction Tool in Cognitively Normal Elderly by Hsu, David C., MD, Munro, Catherine E., BA, Rao, Vaishnavi, BS, Chute, Margaret, BA, Dagley, Alexander, BA, Schultz, Aaron, PhD, Chhatwal, Jasmeer, MD, PhD, Hedden, Trey, PhD, Amariglio, Rebecca, PhD, Mormino, Elizabeth, PhD, Donovan, Nancy, MD, Rentz, Dorene, PsyD, Johnson, Keith, MD, Sperling, Reisa, MD, MMSc, Marshall, Gad, MD

Get full text

A Closer Look at No-Till Farming by Giere, John P., Johnson, Keith M., Perkins, John H.

Get full text

Investigating the Association between Depressive Symptoms and Cortical Tau Across the Alzheimer's Disease Spectrum by Gatchel, Jennifer R., MD, PhD, Donovan, Nancy J., MD, Blacker, Deborah, ScD, MD, Schultz, Aaron P., PhD, Becker, Alex, PhD, Chhatwal, Jasmeer, MD, PhD, Papp, Kathryn V., PhD, Amariglio, Rebecca E., Phd, Rentz, Dorene M., PsyD, Sperling, Reisa A., MD, Johnson, Keith A., MD, Marshall, Gad A., MD

Get full text

The 2011 ESRD Prospective Payment System and the Survival of an Endangered Species: The Perspective of a Not-for-Profit Medium-Sized Dialysis Organization by Johnson, Douglas S., MD, Meyer, Klemens B., MD, Johnson, H. Keith, MD

Get full text

Anemia Management and Association of Race With Mortality and Hospitalization in a Large Not-for-Profit Dialysis Organization by Servilla, Karen S., MD, Singh, Ajay K., MD, Hunt, William C., MA, Harford, Antonia M., MD, Miskulin, Dana, MD, MS, Meyer, Klemens B., MD, Bedrick, Edward J., PhD, Rohrscheib, Mark R., MD, Tzamaloukas, Antonios H., MD, Johnson, H. Keith, MD, Zager, Philip G., MD

“…Background The optimal hemoglobin target and possible toxicity of epoetin therapy in hemodialysis patients are controversial. Previous studies suggest that…”
Get full text

Relationship of Florbetapir F18 PET Amyloid Plaque Neuroimaging with Future Cognitive Decline over 36 Months by Hochstetler, Helen, PharmD, Doraiswamy, P. Murali, MD, Sperling, Reisa A., MD, Johnson, Keith A., MD, Reiman, Eric, MD, Sabbagh, Marwan N., MD, Sadowsky, Carl H., MD, Joshi, Abhinay D., MS, Lu, Ming, MD, Mintun, Mark A., MD, Pontecorvo, Michael J., PhD, Skovronsky, Daniel M., MD

Get full text

Material properties, biocompatibility, and wear resistance of the Medtronic pyrolytic carbon by Leuer, L H, Gross, J M, Johnson, K M

“…Pyrolytic carbon is the material of choice for components in the majority of heart valves available today. Many manufacturers have vertically integrated their…”
Get more information